OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2024.14347 OL-27-5-14347 Retraction [Retracted] Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma ZhouPeng LiXuemin 05 2024 19 03 2024 27 5 215 Copyright: © 2024 Zhou and Li 2024 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.

Oncol Lett 18: 307–313, 2019; DOI: 10.3892/ol.2019.10331

Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that the Transwell cell migration and invasion assay data shown in Fig. 4A and B on p. 312 had already appeared in several previously published articles written by different authors at different research institutes. In addition, the second (more senior) author listed on the paper (Xuemin Li), who was also included as the author for correspondence, claimed that he had no knowledge of this paper's submission, and requested that it be withdrawn from the publication.

Owing to the fact that the contentious data in the above article had already been published prior to its submission to Oncology Letters, the Editor has agreed with the request that this paper should be retracted from the Journal. The Editor apologizes to the readership for any inconvenience caused.